Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 769-777     DOI: 10.31083/j.rcm2203083
Special Issue: State-of-the-Art Cardiovascular Medicine in Asia 2021
Review Previous articles | Next articles
Role of the ACE2/Ang-(1-7)/Mas axis in glucose metabolism
Shiyuan Zhao1, Wenxue Sun1, Pei Jiang1, 2, *()
1Department of Clinical Pharmacy, Jining First People's Hospital, Jining Medical University, 272000 Jining, Shandong, China
2Department of Clinical & Translational Medicine, Jining Life Science Center, 272000 Jining, Shandong, China
Download:  PDF(1456KB)  ( 476 ) Full text   ( 25 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
The renin-angiotensin system (RAS) helps to regulate cardiovascular function, the maintenance of electrolyte and fluid balance, and blood pressure. The RAS contains two axes; the angiotensin-converting enzyme/angiotensin II/Ang II type 1 receptors (ACE/Ang II/AT1) classic axis, which has a role in regulating blood pressure, vascular oxidative stress, coagulation, and cellular proliferation. The other is the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptors (ACE2/Ang-(1-7)/Mas) axis, which can inhibit the former axis, improve fat metabolism, reduce inflammation and oxidative stress, and enhance glucose tolerance and insulin sensitivity. The ACE2/Ang-(1-7)/Mas axis is found in blood vessels, kidneys, liver, pancreas and the brain. It can protect the body from abnormalities in glucose metabolism. The ACE2/Ang-(1-7)/Mas axis can enhance glucose tolerance and improve insulin sensitivity by protecting pancreatic β cells, increasing insulin secretion, improving glucose metabolism in adipose tissue, enhancing glucose uptake by skeletal muscle, and inhibiting hepatic gluconeogenesis. This article reviews the main characteristics and functions of the ACE2/Ang-(1-7)/Mas axis and its regulation of glucose metabolism in order to demonstrate its potential as a target for the treatment of metabolic diseases such as diabetes.
Key words:  ACE2/Ang-(1-7)/Mas axis      Glucose metabolism      Renin-angiotensin system      Pancreatic β cells      Insulin resistance      Diabetes     
Submitted:  23 June 2021      Revised:  27 July 2021      Accepted:  09 August 2021      Published:  24 September 2021     
Fund: 
81602846/National Natural Science Foundation of China
tsqn201812159/Taishan Scholar Project of Shandong Province
2019SMNS012/Key Research and Development Program of Jining Science and Technology
*Corresponding Author(s):  Pei Jiang     E-mail:  jiangpeicsu@sina.com

Cite this article: 

Shiyuan Zhao, Wenxue Sun, Pei Jiang. Role of the ACE2/Ang-(1-7)/Mas axis in glucose metabolism. Reviews in Cardiovascular Medicine, 2021, 22(3): 769-777.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203083     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/769

[1] Raffaele Galiero, Alfredo Caturano, Erica Vetrano, Arturo Cesaro, Luca Rinaldi, Teresa Salvatore, Raffaele Marfella, Celestino Sardu, Elisabetta Moscarella, Felice Gragnano, Paolo Calabrò, Ferdinando Carlo Sasso. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 755-768.
[2] Levent Altınay, Erdem Çetin. The comparison between the effects of aspirin and clopidogrel monotherapy on postoperative bleeding in diabetic patients after off-pump coronary artery bypass surgery[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 975-981.
[3] Eyad Abuelgasim, Suleyman Shah, Biyaser Abuelgasim, Nikita Soni, Ashvin Thomas, Mustafa Elgasim, Amer Harky. Clinical overview of diabetes mellitus as a risk factor for cardiovascular death[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 301-314.
[4] Pierre Sabouret, Pier Paolo Bocchino, Giuseppe Biondi-Zoccai. New anti-diabetic agents: major advances with unanswered questions[J]. Reviews in Cardiovascular Medicine, 2020, 21(4): 489-492.
[5] Niloofar Deravi, Mobina Fathi, Kimia Vakili, Shirin Yaghoobpoor, Marzieh Pirzadeh, Melika Mokhtari, Tara Fazel, Elahe Ahsan, Samad Ghaffari. SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: a systematic review[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 385-397.
[6] María M. Adeva-Andany, Carlos Fernández-Fernández, Natalia Carneiro-Freire, Elvira Castro-Quintela, Ana Pedre-Piñeiro, Mónica Seco-Filgueira. Insulin resistance underlies the elevated cardiovascular risk associated with kidney disease and glomerular hyperfiltration[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 41-56.
[7] Alan S. Brown, Karol E. Watson. Statin Intolerance[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 9-19.
[8] Jun Zhang, Natalia de Albuquerque Rocha, and Peter A. McCullough. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 13-19.
[9] Prakash C. Deedwania. Management of Patients With Stable Angina and Type 2 Diabetes[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 105-113.
[10] Peter A. McCullough, Maria Rosa Costanzo, Marc Silver, Bruce Spinowitz, Jun Zhang, Norman E. Lepor. Novel Agents for the Prevention and Management of Hyperkalemia[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 140-155.
[11] Jeremy P. Berman, Sanjum S. Sethi, Michael E. Farkouh. Strategies for Management of Stable Coronary Disease in Type 2 Diabetes Mellitus[J]. Reviews in Cardiovascular Medicine, 2013, 14(S1): 50-58.
[12] Arthur R. Menezes, Carl J. Lavie, James J. DiNicolantonio, James O'Keefe, Daniel P. Morin, Sammy Khatib, Franz H. Messerli, Richard V. Milani. Cardiometabolic Risk Factors and Atrial Fibrillation[J]. Reviews in Cardiovascular Medicine, 2013, 14(2-4): 73-81.
[13] David S.H. Bell, Harshal R. Patil, James H. O'Keefe. Divergent Effects of Various Diabetes Drugs on Cardiovascular Prognosis[J]. Reviews in Cardiovascular Medicine, 2013, 14(2-4): 107-122.
[14] Kasia J. Lipska, Mikhail Kosiborod. Management of Blood Glucose in Patients With Acute Coronary Syndromes[J]. Reviews in Cardiovascular Medicine, 2012, 13(2-3): 77-88.
[15] Norman E. Lepor, Peter A. McCullough. Best of the ACC 2010 Scientific Session[J]. Reviews in Cardiovascular Medicine, 2010, 11(3): 153-163.
No Suggested Reading articles found!